Charles River Laboratories stock (US1591881009): Q1 earnings beat with updated FY guidance

FierceBiotechAlumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects

Endpoints NewsSupreme Court preserves mail access for abortion pill

FierceBiotechAardvark to dig into phase 3 data early after FDA imposes hold

Siemens HealthineersSiemens Healthineers Wins Key US Clearances As Valuation Gap Widens - simplywall.st

BioNTechBioNTech’s Clinical and Corporate Overhaul: Cancer Data Improves as COVID Era Ends - AD HOC NEWS

Every GreenBiotech Just Hit Fast Forward. Is Europe’s Seed Sector Ready? - seedworld.com

IQVIAIQVIA And Kexing Biopharm Advance Global Biosimilar Expansion Through AI Enabled Strategic Collaboration - BioPharma APAC

IlluminaCorvex Funds tied to Illumina (NASDAQ: ILMN) sell shares and partly unwind equity swaps - Stock Titan

FierceBiotechChutes & Ladders—AC Immune CEO bids adieu

Eli LillyIs Eli Lilly Going To $1,100? - 24/7 Wall St.

Clinical OMICsAI in Healthcare: Symposium Insights

FierceBiotechSignant Health buys Ametris to unite data streams in clinical trials